Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst
Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst
Needham initiated coverage on Inari Medical Inc (NASDAQ:NARI), noting it as a leader in the very large and underpenetrated market for venous thrombectomy.
尼德姆开始对Inari Medical Inc（纳斯达克股票代码：NARI）进行报道，指出该公司在庞大且渗透率不足的静脉血栓切除术市场中处于领先地位。
Inari Medical projects an annual patient population of 280,000 with pulmonary embolism (PE) in the U.S., equating to a total available market (TAM) of $2.8 billion for its FlowTriever product.
Inari Medical预计，美国每年的肺栓塞（PE）患者人数为28万人，相当于其FlowTriever产品的总可用市场（TAM）为28亿美元。
Additionally, the company estimates a yearly count of 430,000 patients with deep vein thrombosis (DVT), resulting in a $3.0 billion TAM for its ClotTriever product. The penetration rates for the PE and DVT markets are approximately 20% and 15%, respectively.
此外，该公司估计，每年有43万名深静脉血栓形成（DVT）患者，从而使其ClotTriever产品的TAM达到30亿美元。私募股权和DVT市场的渗透率分别约为20％和15％。
Needham initiates with a Buy rating and a price target of $72.
Needham最初的评级为买入，目标股价为72美元。
In late 2023, Inari Medical acquired LimFlow SA for $250 million in cash at closing and is eligible to receive up to $165 million in additional payments based on certain commercial and reimbursement milestones, for a total potential transaction value of up to $415 million.
2023年底，Inari Medical在收盘时以2.5亿美元现金收购了LimFlow SA，根据某些商业和报销里程碑，有资格获得高达1.65亿美元的额外付款，潜在交易总额高达4.15亿美元。
The analyst writes that Inari Medical presents a compelling acquisition opportunity.
该分析师写道，Inari Medical提供了一个引人注目的收购机会。
The company aligns with the criteria sought by major medical technology firms, boasting a robust gross margin of approximately 88%, anticipated double-digit revenue growth (projected at around 19% CAGR from 2023 to 2026), and a revenue size approaching $500 million in 2023.
该公司符合主要医疗技术公司寻求的标准，毛利率约为88％，预计将实现两位数的收入增长（预计从2023年到2026年复合年增长率约为19％），2023年的收入规模接近5亿美元。
Furthermore, Inari Medical holds a prominent position in the high-growth venous thrombectomy segment.
此外，Inari Medical在高生长的静脉血栓切除术领域占据突出地位。
Needham identifies potential suitors for acquisition, including Abbott Laboratories Inc (NYSE:ABT), Becton, Dickinson And Co (NYSE:BDX), Boston Scientific Corporation (NYSE:BSX), Medtronic Plc (NYSE:MDT), Koninklijke Philips N.V. (NYSE:PHG), Stryker Corp (NYSE:SYK), Teleflex Inc (NYSE:TFX), and Terumo Corp (OTC:TRUMF) (OTC:TRUMY).
尼德姆确定了潜在的收购者，包括雅培实验室公司（纽约证券交易所代码：ABT）、Becton、Dickinson And Co（纽约证券交易所代码：BDX）、波士顿科学公司（纽约证券交易所代码：BSX）、美敦力集团（纽约证券交易所代码：MDT）、Koninklijke Philips N.V.（纽约证券交易所代码：PHG）、Stryker Corp（纽约证券交易所代码：SYK）、泰利福公司（纽约证券交易所代码：SYK）、泰利福公司（纽约证券交易所代码：SYK）（纽约证券交易所代码：SYK）、泰利福公司（纽约证券交易所代码：SSE: TFX）和Terumo Corp（场外交易代码：TRUMF）（场外交易代码：TRUMY）。
Needham writes that Inari Medical shares are attractively valued, trading at 5.1x its estimated sales for 2024, showing a 21% premium compared to similar small/mid-cap growth companies with a median estimated EV/S multiple of 4.2x.
尼德姆写道，Inari Medical的股票估值极具吸引力，其2024年预计销售额为5.1倍，与类似的中小型成长型公司相比，溢价了21％，估计EV/S倍数中位数为4.2倍。
Additionally, Inari Medical shares exhibit a 9% premium compared to small/mid-cap companies in the cardiovascular and neuromodulation sector, with a median estimated EV/S multiple of 4.7x.
此外，与心血管和神经调节领域的中小型股公司相比，Inari Medical的股票溢价为9％，估计的EV/S倍数中位数为4.7倍。
Price Action: NARI shares are down 0.27% at $57.40 on the last check Tuesday.
价格走势：在周二的最后一次支票中，NARI股价下跌0.27％，至57.40美元。